Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2019 Society for Neuro-Oncology Annual Meeting

NEXT STORY
Novartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of death
PREV STORY
BeiGene Announces Clinical Data on Tislelizumab Presented at European Society for Medical Oncology (ESMO) Asia 2019 Congress
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Harpoon Therapeutics Appoints Omer Siddiqui as VP Development Operations and Project Management

author_avatar
NASDAQ Market News

GENFIT: Major Milestone achieved with full recruitment of the Phase 2 trial evaluating elafibranor in PBC

GENFIT: Major Milestone achieved with full recruitment of the Phase 2 trial evaluating elafibranor ...

author_avatar
NASDAQ Market News

Preliminary Data from Long-Term Safety Study Support Chronic Use of ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis

author_avatar
NASDAQ Market News